{"links":{"feed":"https://www.erudio.com/reports/tropion-urothelial03-nct07129993/feed.json","html":"https://www.erudio.com/reports/tropion-urothelial03-nct07129993","json":"https://www.erudio.com/reports/tropion-urothelial03-nct07129993.json","markdown":"https://www.erudio.com/reports/tropion-urothelial03-nct07129993.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"tropion-urothelial03-nct07129993"}},"request":"https://www.erudio.com/contact?report=tropion-urothelial03-nct07129993"},"offer":{"cited_clinicians":4,"cited_commentary_sources":7,"verified_hcp_statements":25,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":4},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"tropion-urothelial03-nct07129993"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=tropion-urothelial03-nct07129993","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/tropion-urothelial03-nct07129993","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 25 verified statements · 12 from 4 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-20T23:04:46.964363Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":10,"no_commentary_found":4},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Overall Response Rate - Part A (Phase 2)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":1,"title":"Primary endpoint: Overall Survival - Part B (Phase 3)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":0,"title":"Secondary endpoint: Duration of Response - Part A (Phase 2)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":0,"title":"Secondary endpoint: Progression Free Survival as Assessed by Investigator - Part B (Phase 3)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T6","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":0,"title":"Secondary endpoint: Overall Response Rate - Part B (Phase 3)"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"conditionsModule","source_count":5,"title":"Population and setting"},{"claim_count":8,"coverage":"discussed","id":"T8","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":0,"coverage":"no_commentary_found","id":"T9","registry_field":"armsInterventionsModule.interventions","source_count":0,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T10","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":6,"title":"Post-EV/pembrolizumab unmet need and sequencing uncertainty"},{"claim_count":3,"coverage":"discussed","id":"A2","source_count":3,"title":"TROP2 rationale and expectations for investigation"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Routine-care alternatives and upfront biomarker work-up"},{"claim_count":2,"coverage":"discussed","id":"A4","source_count":2,"title":"Fit-patient trial preference and alternative ADC regimens"}],"counts":{"beyond_population_findings":2,"beyond_population_statements":6,"cited_clinicians":4,"cited_clinicians_by_role":{"physician":1,"physician, Medical oncology":2,"physician, Urology":1},"cited_physicians":4,"cited_sources":9,"claims_by_expression_type":{"comparison":1,"experience":2,"interpretation":5,"opinion":6,"primary_context":4,"question":2,"restatement":3,"unspecified":2},"claims_by_kind":{"protocol_statement":3,"publication_statement":4,"source_observation":18},"clinician_statements":12,"evidence_units":16,"findings":4,"organisational_accounts":3,"people_cited":4,"people_identity_verified":4,"people_total":4,"screened_sources":12,"verified_claims":25},"findings_index":[{"cited_clinicians":2,"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":4},"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":2,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Platinum after EV/pembrolizumab: where clinicians split on its activity","title_holders":{"cited_claim_ids":["claim-076b80fdc0ba6df14f99","claim-5c9dca86e1befaece8ff","claim-8543b3295afbad25ec24","claim-1ca399264b83e4ced975"],"clinicians":true,"holders":2,"speakers":2,"view":"split"},"evidence_line":"7 statements from 2 speakers in 5 sources","holder_line":"2 of the 2 named speakers in this finding take a side on this question; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":3,"id":"F2","structure":{"claims":12,"claims_by_group":{"comparisons":1,"experience":1,"questions":0,"restated":6,"views":4},"limitations":3,"links":{"context":0,"support":13},"ma_question":true,"named_voices":3,"passages":8,"sources":5,"sources_by_kind":{"commentary":3,"publication":1,"registry":1}},"title":"TROP2 after EV/pembrolizumab: what speakers say","evidence_line":"12 statements from 3 speakers in 5 sources"},{"cited_clinicians":1,"id":"F3","population":"beyond","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":1},"limitations":3,"links":{"context":1,"support":2},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Sequencing: what speakers say","evidence_line":"2 statements from 1 speaker in 2 sources"},{"cited_clinicians":1,"id":"F4","population":"beyond","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":2},"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":1,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"After EV/pembrolizumab: what speakers say","evidence_line":"4 statements from 1 speaker in 3 sources"}],"open_question":{"basis":"From finding F1 (7 statements from 2 speakers in 5 sources)","cited_claim_ids":["claim-15363145be24ce5b14de","claim-076b80fdc0ba6df14f99","claim-5c9dca86e1befaece8ff","claim-f1cccd226f2df31e4a43","claim-8543b3295afbad25ec24","claim-1ca399264b83e4ced975","claim-b6c0e607bef309f44708"],"finding_ids":["F1"],"question":"What randomized evidence do clinicians need from TROPION-Urothelial03 on response and survival with datopotamab deruxtecan plus platinum versus gemcitabine plus platinum in advanced urothelial carcinoma progressing after enfortumab vedotin plus pembrolizumab, given differing accounts of platinum activity?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Accounts describe modest platinum activity; one relayed review emphasizes retained activity"},{"id":"section-2","level":2,"title":"One physician account calls TROP2 rational; other accounts highlight distinct research directions"},{"id":"section-3","level":2,"title":"Beyond the trial population"},{"id":"section-4","level":3,"title":"One physician account lists current options; one relayed review urges upfront FGFR3/HER2 testing"},{"id":"section-5","level":3,"title":"One relayed talk favors trials for fit patients after EV plus pembrolizumab"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, sequential, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F2","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Response Rate - Part A (Phase 2)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T3","label":"Primary endpoint: Overall Survival - Part B (Phase 3)"},{"findings":[],"id":"T4","label":"Secondary endpoint: Duration of Response - Part A (Phase 2)"},{"findings":[],"id":"T5","label":"Secondary endpoint: Progression Free Survival as Assessed by Investigator - Part B (Phase 3)"},{"findings":[],"id":"T6","label":"Secondary endpoint: Overall Response Rate - Part B (Phase 3)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":4}],"id":"T7","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":4}],"id":"T8","label":"The comparison"},{"findings":[],"id":"T9","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2}],"id":"T10","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-20T23:04:46.964363Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-20T23:14:24Z","record_hash":"0af954f1656f2c6f7bfa20bcd79cc8990178fa999bf0b90898befc925b2908ed","release_hash":"a47fa664a78565558530a560d4fe9baada48d52d5c3418a9573127dc2193fdfb","report_id":"erudio-nct07129993","run_id":"93fbf89c-912f-4bb7-8113-9fe147c72556","schema_version":"5.0","slug":"tropion-urothelial03-nct07129993","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A urologist frames TROPION-Urothelial03 as addressing platinum’s limited activity, while a speaker’s relayed assessment describes platinum as still active; the estimates use different measures and are not directly comparable. The urologist cites TROP2 expression as grounds for investigation, not demonstrated benefit. Trial-specific commentary is limited; FGFR3/HER2 testing and trials for fit patients provide treatment-choice context. These accounts cannot establish comparative benefit or trial-specific tolerability.","examples":[],"meta_description":"12 sources screened · 25 verified statements (12 from clinicians verified by NPI or staff page) from 9 sources · 4 findings. Updated Nov 20, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-20T23:14:24Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":12},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on platinum chemotherapy, biomarker-directed therapies, emerging antibody-drug conjugates and clinical trials after EV plus pembrolizumab.","13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 43 sources about other trials or topics are not included.","The available discussion is concentrated in public posts and short summaries. Full talks and reviews are not represented, so the reasoning behind some estimates and preferences cannot be fully assessed.","Reposts and quoted posts do not establish additional independent HCP views or agreement.","Platinum estimates differ in endpoint, wording and evidence source. They should not be combined into a single expected response or survival estimate for the trial's comparator.","The review's lack of a signal favoring cisplatin over carboplatin is not evidence of equivalence.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The TROPION-Urothelial03 material used here describes methods and prospective expectations. Supporting observations from other Dato-DXd studies concern different regimens and, for TROPION-Lung04, a different cancer.","Post dates are not presentation or session dates and do not establish changes in a clinician's opinion."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":6,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":7,"methods":2},"count":9,"evidence_window":{"end":"2026-11-13","start":"2026-02-28"},"retrieval_snapshot":"2026-11-20T22:41:29.236347Z","timeline":[{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W38"},{"count":1,"week":"2026-W45"},{"count":2,"week":"2026-W46"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT07129993:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07129993:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42142358","quote_policy":"no_derivatives"},{"id":"openfda:f91c48da-68d1-4aa7-89b8-d84a3e8b629b:20261109","quote_policy":"short_quote_link_out"},{"id":"openfda:93edf309-993c-48ec-be90-27d89c86b62b:20261112","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7465752492023336960","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027749116931883219:33947609-9aff-4654-9ffb-de52e32c62f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027851437972087086:fb269e69-75f9-4506-aabe-979b1f8785c6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070882354189545602:7f620333-69b9-4221-9c1b-2bf23c5fd948","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090816291867066487:c51df607-8160-438d-a766-5514265dcd6e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099513587865645510:f272f8e0-25db-4f12-a63e-d1fb2479c702","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100911474352767471:7e17a0cd-1467-4b7f-939b-51bfc27999d9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2104262291780731355:d21d3d79-3d47-477f-996c-9ff1a88d323d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118660973615845859:0ecbb745-95a8-4c9c-80f1-3b605e00b9f7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120635047023886588:85509a16-224a-4f0d-b82c-c34b0edfaf17","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120879662511403378:0a9762f1-f8ba-435c-9437-abc39c97c67c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2120896801343455565:3eec0482-5a22-471d-9ec3-d36525b51bda","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":11,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":12},"count":12,"evidence_window":{"end":"2026-11-13","start":"2026-02-28"},"retrieval_snapshot":"2026-11-20T22:41:29.236347Z","timeline":[{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W26"},{"count":1,"week":"2026-W34"},{"count":2,"week":"2026-W38"},{"count":1,"week":"2026-W39"},{"count":1,"week":"2026-W45"},{"count":3,"week":"2026-W46"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":3,"other":0,"podcast":0,"publication":6,"registry":1,"regulatory":0,"x_thread":15,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":["Datroway"],"label":"datopotamab deruxtecan","slug":"datopotamab-deruxtecan"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Urothelial carcinoma","slug":"urothelial-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"TROPION-Urothelial03","aliases":["TROPION-Urothelial03","DS1062-328","Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)"],"brief_title":"Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma","collaborators":["AstraZeneca"],"conditions":["Urothelial Cancer","Bladder Cancer"],"display_condition":"advanced urothelial carcinoma after enfortumab vedotin plus pembrolizumab","display_interventions":[["datopotamab deruxtecan"]],"enrollment":{"count":630,"type":"ESTIMATED"},"interventions":[{"name":"Dato-DXd","synonyms":["Datopotamab Deruxtecan"],"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07129993","official_title":"A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2029-06-01","type":"ESTIMATED"},"primary_endpoints":[{"description":"Overall Response Rate (ORR) is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or confirmed Partial Response (PR). As assessed by investigator per RECIST v1.1","measure":"Overall Response Rate - Part A (Phase 2)","timeFrame":"From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months"},{"description":"Progression Free Survival (PFS) is defined as the time from randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first. As assessed by BICR per RECIST v1.1","measure":"Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3)","timeFrame":"From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months"},{"description":"Overall Survival (OS) is defined as the time from randomization to death due to any cause.","measure":"Overall Survival - Part B (Phase 3)","timeFrame":"From Phase 3 randomization to death due to any cause, up to approximately 38 months"}],"registered_date":{"date":"2025-08-19","type":"ACTUAL"},"registry_last_updated":"2026-08-20","registry_url":"https://clinicaltrials.gov/study/NCT07129993","short_name":"TROPION-Urothelial03","short_name_basis":"canonical_name","sponsor":"Daiichi Sankyo","start_date":{"date":"2025-09-26","type":"ACTUAL"},"study_design":"interventional, randomized, sequential, phase2, phase3","study_ids":[{"id":"DS1062-328","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}